Dr. Gerd Krick, Chairman of the Fresenius Supervisory Board, celebrates 75th birthday
Born in Dresden, Germany in 1938, Dr. Krick earned a doctorate in mechanical engineering in 1969. After working as Managing Director of a medical technology company, he joined the former Dr. E. Fresenius KG in 1975 as Managing Director for research & development, production and technology. This began a very successful period in which Dr. Krick played a leading role in developing the company's first dialyzers and dialysis machines, and helped make dialysis-related activities a core business of Fresenius.
When Fresenius was converted into a stock corporation in 1981, Dr. Krick joined the Management Board of the newly established Fresenius AG, with responsibility for medical devices. In 1991, he was appointed Deputy Chairman of the Management Board. The next year he became CEO, succeeding Dr. Hans Kröner, who along with his wife, Else Kröner, had built Fresenius from a small family business into a major enterprise.
Fresenius grew significantly during Dr. Krick's tenure as CEO. Annual sales increased 10 times to €7.5 billion in 2002, and the number of employees rose ninefold to more than 63,000. An exceptional entrepreneurial success was the 1996 acquisition of the U.S. dialysis company National Medical Care and its merger with the dialysis business of Fresenius. Today, Fresenius Medical Care is the world market leader in dialysis products and services.
After turning the CEO position over to Ulf Mark Schneider in 2003, Dr. Krick became Chairman of the Supervisory Board. In recognition of his accomplishments, the German business monthly Manager Magazin named Dr. Krick to its Hall of Fame in 2011.
"We are very grateful to Gerd Krick for his unique and outstanding contributions to our company," said Ulf Mark Schneider, CEO of Fresenius. "Under his guidance and leadership, Fresenius developed into a significant global player in the health care industry."
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Fresenius AG (SE)
Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2012, Group sales were €19.3 billion. On June 30, 2013, the Fresenius Group had 173,325 employees worldwide.
For more information visit the Company's website at www.fresenius.com.